Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MAZE | PRESS-RELEASE | neutral | 4/10 | Maze Therapeutics reported Q2 2026 EPS of -$0.76, missing consensus of -$0.70 by 8.6%, with no license revenue for the q | Aug 11, 2026 |
| AQST | PRESS-RELEASE | neutral | 5/10 | Aquestive Therapeutics reported Q2 2026 revenue of $13.8M (+38% YoY) and GAAP EPS of -$0.18, beating consensus EPS of -$ | Aug 11, 2026 |
| IKT | PRESS-RELEASE | neutral | 5/10 | Inhibikase Therapeutics reported Q2 2026 net loss of $0.11 per share, in line with the year-ago period but with a net lo | Aug 11, 2026 |
| ERAS | PRESS-RELEASE | neutral | 5/10 | No summary provided | Aug 11, 2026 |
| TSHA | PRESS-RELEASE | neutral | 5/10 | Taysha Gene Therapies reported Q2 2026 EPS of -$0.13, missing consensus of -$0.11 by 18.2%, with zero revenue vs. $1.99M | Aug 11, 2026 |
| ACHV | PRESS-RELEASE | bearish | 7/10 | Achieve Life Sciences reported Q2 2026 EPS of -$0.80, significantly missing the consensus estimate of -$0.16, driven by | Aug 11, 2026 |
| FENC | PRESS-RELEASE | bullish | 6/10 | Fennec Pharmaceuticals reported Q2 2026 net product sales of $17.1M, up 78% YoY from $9.7M, and GAAP diluted EPS of $0.0 | Aug 11, 2026 |
| VOR | PRESS-RELEASE | neutral | 3/10 | Vor Bio reported Q2 2026 financial results with net loss of $62.8M, cash of $466.1M (plus $48.4M from July ATM sales), a | Aug 11, 2026 |
| MREO | PRESS-RELEASE | neutral | 4/10 | Mereo BioPharma reported Q2 2026 results with zero revenue and a net loss of $7.0M, in line with consensus EPS of -$0.01 | Aug 11, 2026 |
| SGMT | PRESS-RELEASE | neutral | 5/10 | Sagimet Biosciences reported Q2 2026 net loss of $14.0 million ($0.26 per share), wider than the $10.4 million loss in Q | Aug 11, 2026 |
| BCAX | PRESS-RELEASE | mixed | 6/10 | Bicara Therapeutics reported Q2 2026 results with a net loss of $0.82 per share, slightly better than the $0.83 consensu | Aug 11, 2026 |
| TARA | PRESS-RELEASE | neutral | 4/10 | Protara Therapeutics reported Q2 2026 net loss of $21.7M ($0.36/share), widening from a $15.0M loss in Q2 2025, driven b | Aug 11, 2026 |
| KLRS | PRESS-RELEASE | neutral | 4/10 | Kalaris Therapeutics reported Q2 2026 EPS of -$0.48, a 7.1% beat vs consensus of -$0.49, but net loss widened slightly t | Aug 11, 2026 |
| TOVX | PRESS-RELEASE | neutral | 5/10 | Theriva Biologics reported Q2 2026 financial results with a net loss of $3.2M ($0.07 per share) vs $13.1M ($1.93 per sha | Aug 11, 2026 |
| LBRX | PRESS-RELEASE | bullish | 7/10 | LB Pharmaceuticals reported Q2 2026 net loss of $51.6M ($1.71/share) vs $4.9M a year ago, reflecting heavy R&D investmen | Aug 11, 2026 |
| AURA | PRESS-RELEASE | bearish | 6/10 | Aura Biosciences reported Q2 2026 EPS of -$0.48, a 33.3% miss vs consensus of -$0.38, with revenue of $0. The net loss w | Aug 11, 2026 |
| CALC | PRESS-RELEASE | neutral | 4/10 | CalciMedica reported Q2 2026 financial results with a net loss of $7.7M ($0.45/share) vs $6.0M ($0.40/share) in Q2 2025, | Aug 11, 2026 |
| PRLD | PRESS-RELEASE | bullish | 5/10 | Prelude Therapeutics reported Q2 2026 EPS of -$0.14, beating consensus of -$0.18 by 22.2%, and generated $5.7M in revenu | Aug 11, 2026 |
| GANX | PRESS-RELEASE | bullish | 6/10 | Gain Therapeutics reported Q2 2026 EPS of -$0.11, beating consensus of -$0.15 by 26.7%, with net loss narrowing to $4.7M | Aug 11, 2026 |
| TNGX | PRESS-RELEASE | bullish | 7/10 | Tango Therapeutics reported Q2 2026 net loss of $0.37 per share, slightly wider than the $0.35 loss in Q2 2025, with zer | Aug 11, 2026 |
| ACIU | PRESS-RELEASE | bullish | 7/10 | AC Immune received FDA Fast Track designation and IND clearance for its wholly owned anti-alpha-synuclein active immunot | Aug 11, 2026 |
| STTK | PRESS-RELEASE | neutral | 5/10 | Shattuck Labs reported Q2 2026 net loss of $0.12 per share, in line with consensus of -$0.12, with no revenue. The key p | Aug 11, 2026 |
| HROW | PRESS-RELEASE | bearish | 8/10 | No summary provided | Aug 10, 2026 |
| PROK | PRESS-RELEASE | neutral | 5/10 | ProKidney reported Q2 2026 financial results with no revenue or EPS guidance to analyze, as the company is pre-commercia | Aug 10, 2026 |
| DMRA | PRESS-RELEASE | bearish | 7/10 | Damora Therapeutics reported Q2 2026 EPS of -$0.62, a 67.6% miss versus consensus of -$0.37, driven by sharply higher R& | Aug 10, 2026 |
| VERA | PRESS-RELEASE | mixed | 7/10 | Vera Therapeutics reported Q2 2026 net loss of $109.5M (-$1.52 EPS), wider than the $76.5M loss in Q2 2025 and a miss vs | Aug 10, 2026 |
| SANA | PRESS-RELEASE | neutral | 4/10 | Sana Biotechnology reported Q2 2026 GAAP net loss of $63.6M ($0.22/share), slightly narrower than the year-ago $93.8M lo | Aug 10, 2026 |
| OLMA | PRESS-RELEASE | neutral | 4/10 | Olema Oncology's Q2 2026 net loss widened to $63.2M (vs $43.8M a year ago) on higher R&D and G&A spending, but cash of $ | Aug 10, 2026 |
| BBIO | PRESS-RELEASE | mixed | 6/10 | BridgeBio reported Q2 2026 total revenues of $243.7M (+120.5% YoY), driven by $222.4M in Attruby net product revenue (+2 | Aug 10, 2026 |
| SEPN | PRESS-RELEASE | neutral | 4/10 | Septerna reported Q2 2026 financial results highlighting a net loss of $13.0M (EPS -$0.29) vs consensus of -$0.48, a 39. | Aug 10, 2026 |